To evaluate the safety and pharmacokinetic characteristics after the administration of JC-001 and JLP-1901
An open-label, randomized, single administration, full replicated crossover phase 1 clinical trial to compare pharmacokinetics and safety between JLP-1901 and JC-001 in healthy subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
administration of JLP-1901
administration of JC-001(tenofovir)
Bundang CHA university global clinical trials center Institutional Review Board
Gyeonggi-do, Bundang-gu, South Korea
AUC over 24H of JLP-1901
AUC over 24H
Time frame: 24 hours
Cmax of JLP-1901
Cmax
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.